Raymond James Financial
KTTA icon

Raymond James Financial’s Pasithea Therapeutics KTTA Stock Holding History

Raymond James Financial’s Portfolio KTTA Stock Details KTTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,584
Closed -$1.14K – 5906
2025
Q2 		$1.14K Buy
+1,584
New +$1.73K ﹤0.01% 6535

Other funds holding KTTA

AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Raymond James Financial's KTTA Position: Q3 2025 in Review

Raymond James Financial sold out of Pasithea Therapeutics (KTTA) in Q3 2025, closing a stake of 1,584 shares — an estimated $1.14K sold.

Raymond James Financial first reported a position in KTTA in Q2 2025 and held it in 1 quarter. The position peaked at $1.14K in Q2 2025. 19 funds tracked by Wall St. Rank hold KTTA as of Q3 2025.

  • Raymond James Financial reported no remaining Pasithea Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 1,584 Pasithea Therapeutics shares in Q3 2025, an estimated $1.14K.
  • Raymond James Financial first reported a position in Pasithea Therapeutics in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Pasithea Therapeutics position peaked at $1.14K in Q2 2025.
  • 19 funds tracked by Wall St. Rank held Pasithea Therapeutics as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.